Diabetes mellitus (DM) is a factor in the hematopoietic cell transplantation-comorbidity index. However, the impact of pretransplant DM on morbidity and cause-specific non-relapse mortality (NRM) remains unclear. We performed a retrospective study with registry data that included a total of 7626 patients who underwent their first allogeneic hematopoietic SCT (HSCT) between 2007 and 2010. The median age was 44 years (range 0-88). Compared with patients without pre-transplant DM (non-DM group, n = 7248), patients with pre-transplant DM (DM group, n = 378) were older and were more likely to have high-risk disease, a reduced-intensity conditioning regimen and GVHD prophylaxis using tacrolimus. Multivariate analyses showed that pre-transplant DM was associated with increased risks of NRM (hazard ratio (HR)1.46, 95% confidence interval (CI) 1.21-1.76, P o 0.01) and infection-related NRM (HR 2.08, 95% CI 1.58-2.73, P o 0.01). The presence of pre-transplant DM was associated with an increased risk of overall mortality in a multivariate analysis (HR 1.55, 95% CI 1.35-1.78, P o0.01). In conclusion, pre-transplant DM was a risk factor for NRM, particularly infection-related mortality, after allogeneic HSCT. To improve the clinical outcome in patients with DM, the benefits of strict infection control and appropriate glycemic control should be explored in future trials.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) has become an integral part of treatment for hematological malignancies. The risk of nonrelapse mortality (NRM) after allogeneic HSCT has decreased significantly over the past few decades. [1] [2] [3] [4] However, the risk of NRM is still high in elderly patients and patients with comorbidities. 4 Sorror et al. 5 established a hematopoietic cell transplantation-comorbidity index (HCT-CI) scoring system to predict the risk of NRM using pre-transplant parameters. Previous studies that assessed the impact of HCT-CI only demonstrated its impact on the overall clinical outcome. 5, 6 However, detailed information about the risk of each morbidity and mortality in patients with each comorbidity is necessary so that we can intervene efficiently to reduce the risk of complications, which could be expected to improve the overall outcome.
Regarding pre-transplant diabetes mellitus (DM), Derr et al. 7 reported that pre-transplant hyperglycemia was associated with an increased risk of infectious diseases. However, they did not assess the impact of pre-transplant hyperglycemia on GVHD because their study mainly included patients who underwent autologous HSCT. In addition, several papers have reported that peritransplant DM was associated with an increased risk of NRM. [8] [9] [10] Our group previously showed that preengraftment hyperglycemia could be a risk factor for infectious diseases, acute GVHD and NRM. 9 However, post-transplant hyperglycemia can be caused by the post-transplant complications such as infectious diseases, which clearly increase the risk of subsequent NRM. 11, 12 Therefore, the impact of pre-transplant DM on morbidity and cause-specific NRM remains unclear.
The prevalence of DM is increasing worldwide. [13] [14] [15] The number of HSCT recipients complicated with DM is also expected to increase. Thus, it is important to explore methods for improving the outcome of patients with DM in allogeneic HSCT. If we could identify morbidities which have a greater risk in patients with DM, we may be able to prevent such morbidities specifically in patients with DM in addition to glucose control, as in our previous report. 16 In this study, we retrospectively assessed the impact of pretransplant DM on the clinical outcome after allogeneic HSCT using the registry database of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). 17 
PATIENTS AND METHODS Patients
The clinical data were obtained from the registry database of the Transplant Registry Unified Management Program provided by the JSHCT. 17 The following patients were included in the study: (i) patients who underwent their first allogeneic HSCT between January 2007 and December 2010, and (ii) patients for whom information was available 1 regarding the presence or absence of pre-transplant DM included in the scoring of HCT-CI. Three patients who did not have information about the overall clinical outcome were excluded. Finally, 7626 patients were included in further analyses. Data about the control of DM and the insulin-based protocols were not available owing to the nature of our registry data. This study was approved by the Institutional Review Board of National Cancer Center, Tokyo, Japan.
Clinical outcomes
Endpoints included OS, PFS, relapse/progression, NRM, infectious diseases and acute GVHD. Acute and chronic GVHD were defined based on the standard criteria. 18, 19 Regarding cause-specific NRM, NRM was categorized according to the major cause of death including infection, GVHD, organ failure and other.
Statistical analysis
A descriptive statistical analysis was performed to assess the patients' characteristics. Medians and ranges are provided for continuous variables and percentages are given for categorical variables. The probabilities of OS and PFS were calculated by the Kaplan-Meier method. A Cox proportionalhazards regression model was used to analyze OS and PFS. The cumulative incidences of engraftment, NRM, GVHD and infections were evaluated using the Fine and Gray model for univariate and multivariate analyses of cumulative incidence. In the competing risk models for engraftment, GVHD and infectious disease, relapse and death before these events were defined as competing risks. In the competing risk models for NRM, relapse was defined as a competing risk. For each cause-specific NRM, relapse and NRM with other causes were defined as competing risks. Factors that were associated with a two-sided P-value of o0.10 in the univariate analysis were included in a multivariate analysis. We used a backward-stepwise selection algorithm and retained only the statistically significant variables in the final model. A two-sided P-value of o0.05 was considered statistically significant. The variables that were evaluated in these analyses were as follows: sex mismatch (female to male vs other), patient's age at the time of HSCT (age ⩾ 40 years vs age o40), disease risk (standard risk vs high risk), stem cell source (BM vs PB stem cells vs cord blood), HLA disparity assessed by serological typing of HLA A, B and DRB1, performance status (0-1 vs 2-4), intensity of the conditioning regimen (myeloablative conditioning vs reduced-intensity conditioning) and ABO mismatch (match vs minor mismatch vs major mismatch/major and minor mismatch). Standard risk was defined as the first CR of acute leukemia or the first chronic phase of CML or non-malignant diseases. High risk was defined as other diseases. The intensity of the conditioning regimen was defined as described previously. 20, 21 All statistical analyzes were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0, Dr Yoshinobu Kanda, Saitama, Japan). 22 More precisely, it is a modified version of R commander (version 1.6-3, Dr Yoshinobu Kanda) that was designed to add statistical functions that are frequently used in biostatistics. Table 1 summarizes the patients' characteristics. Among the 7626 patients, 378 (5%) had pre-transplant DM (the DM group). Compared with patients without pre-transplant DM (the non-DM group), the DM group included significantly older patients, more patients with high-risk disease, more patients who received a reduced-intensity conditioning regimen and more patients who received tacrolimus.
RESULTS

Patients' characteristics
In the DM group, 259 (69%) and 119 patients (31%) were classified as HCT-CI score = 1-2 and ⩾ 3, respectively. On the other hand, in the non-DM group, 1476 (20%) and 784 patients (11%) were classified as HCT-CI score = 1-2 and ⩾ 3, respectively. We also calculated the HCT-CI score without including the DM score to independently assess the impact of DM. When we excluded the DM score, more patients in the DM group were classified as HCT-CI score ⩾ 1 and this proportion was higher than that in the non-DM group (54 vs 32%, P o0.01). Supplementary Table 1 shows a detailed analysis of the comorbidities other than DM in each group. Patients in the DM group were more likely to be complicated by arrhythmia, cerebrovascular disease, cardiac disease, mild hepatic disease, psychiatric disturbance, obesity and prior solid tumor than those in the non-DM group.
Infections
The cumulative incidence of all documented infections at 1 year after HSCT in the DM group was significantly higher than in the non-DM group (61.5 vs 52.3%, P o 0.01, Figure 1a ). However, in a multivariate analysis, pre-transplant DM was not associated with an increased risk of documented infections. The cumulative incidence of fungal infection at 1 year after HSCT in the DM group was significantly higher than that in the non-DM group (14.9 vs 10.0%, P = 0.02, Figure 1b ). When we focused on the species of fungal infection, there was no significant difference in the cumulative incidence of aspergillus or candida infection between the two groups. Meanwhile, the cumulative incidence of mucor infection at 1 year in the DM group was significantly higher than that in the non-DM group (1.1 vs 0.1%; P o 0.01). In a multivariate analysis, pre-transplant DM was significantly associated with an (20) 784 (11) Abbreviations: CB = cord blood; DM = diabetes mellitus; HCT-CI = hematopoietic cell transplantation-comorbidity index; MAC = myeloablative conditioning; PBSC = PB stem cell; PS = performance status; RIC = reduced-intensity conditioning.
Pre-transplant DM and clinical outcome K Takano et al increased risk of mucor infection (hazard ratio (HR) 9.91, 95% confidence interval (CI) 2.99-32.88, P o 0.01). There were no significant differences in the cumulative incidences of bacterial and viral infections at 1 year after HSCT between the groups.
Acute GVHD There was no difference in the cumulative incidence of grade II-IV acute GVHD between the two groups (34.7 vs 34.5%, P = 0.79).
There was also no significant difference in the cumulative incidence of grade III-IV acute GVHD between the groups (10.6 vs 11.8%, P = 0.48). Pre-transplant DM was not a risk factor for acute GVHD in multivariate analyses.
NRM
The median follow-up period of survivors was 583 days (range, 24-1712 days) after HSCT. Patients in the DM group had a significantly higher incidence of 1-year NRM than those in the non-DM group (36.9% vs 20.1%, P o 0.01, Figure 2a) . In a multivariate analysis, pre-transplant DM was significantly associated with an increased risk of NRM (HR 1.46; 95% CI 1.21-1.76; Po 0.01, Table 2 ).
To exclude the impact of other comorbidities, we calculated the HCT-CI score by excluding the DM score and classified patients into three groups: score = 0, 1-2, ⩾ 3 in the DM group (Figure 2b ) and the non-DM group (Figure 2c) . The cumulative incidence of NRM at 1 year after HSCT in the DM group was significantly higher than that in the non-DM group for each HCT-CI score group. In the DM group, even in patients without any other comorbidities, the cumulative incidence of NRM at 1 year was 35% (Figure 2b) . With respect to the group with score ⩾ 3, the cumulative incidence of NRM at 1 year increased to 52.6%, which was significantly higher than that in the non-DM group (Figures 2b and c) . To further confirm the impact of DM, whilst adjusting for the impact of other HCT-CI factors, we performed a multivariate analysis of NRM that included all of the factors of HCT-CI, and pre-transplant DM was still an independent risk factor for NRM (HR 1.66; 95% CI 1.40-1.97; Po 0.01).
Cause-specific NRM The cumulative incidence of infection-related NRM at 1 year after HSCT in the DM group was significantly higher than that in the non-DM group (16.4 vs 6.7%, P o0.01, Figure 2d) . In a multivariate analysis, pre-transplant DM was associated with an increased risk of infection-related NRM (HR 2.08, 95%CI 1.58-2.73, P o 0.01, Supplementary Table 2 ). When patients were stratified into three groups according to the pathogen of infection-related NRM (bacterial, fungal and viral), the incidence of each pathogenrelated NRM was significantly higher in the DM group. Multivariate analyses showed that pre-transplant DM was associated with an increased risk of each pathogen-related NRM (bacterial, HR 1.53, 95%CI 1.01-2.32, P = 0.04; viral, HR 2.66, 95%CI 1.37-5.17, P o 0.01; fungal, HR 3.51, 95%CI 2.05-6.03, P o 0.01, respectively).
There was no significant difference in the cumulative incidence of GVHD-related NRM between the two groups (3.6 vs 2.0% at 1 year, P = 0.05, Figure 2e) . In a multivariate analysis, pre-transplant DM was not a risk factor of GVHD-related NRM. The cumulative incidence of organ failure-related NRM at 1 year in the DM group was significantly higher than that in the non-DM group (9.8 vs 6.3%, P = 0.01, Figure 2f) . In a multivariate analysis, pre-transplant DM was associated with an increased risk of organ failure-related NRM (HR 1.41, 95%CI 1.01-1.96, P = 0.04).
OS, PFS and relapse The probability of OS at 1 year after HSCT in the DM group was significantly worse than that in the non-DM group (44.7 vs 63.9%, Po 0.01, Figure 3) . A multivariate analysis showed that pretransplant DM was associated with an inferior OS (HR 1.55, 95%CI 1.35-1.78, P o0.001, Table 3 ). The probability of PFS at 1 year in the DM group was also significantly worse than in the Abbreviations: CB = cord blood; CI = confidence interval; DM = diabetes mellitus; HR = hazard ratio; MAC = myeloablative conditioning; PBSC = PB stem cell; PS = performance status; RIC = reduced-intensity conditioning. 
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Cumulative incidence Figure 3 . OS grouped according to the presence of pre-transplant DM (a) and cumulative incidence curves of relapse (b) grouped according to the presence of pre-transplant DM.
non-DM group (40.6 vs 57.4%, P o 0.01). In a multivariate analysis, pre-transplant DM was associated with an inferior PFS (HR 1.44, 95%CI 1.26-1.65, P o 0.01). Regarding relapse, there was no significant difference in the relapse rate between the two groups (30.1 vs 26.2% at 1 year, P = 0.10). Pre-transplant DM was not associated with an increased risk of relapse in a multivariate analysis.
DISCUSSION
In this study, we clearly demonstrated that pre-transplant DM was associated with an increased risk of NRM that led to an inferior OS. These results were consistent with previous reports by Sorror et al. 5, 6 The estimated HR for NRM in a multivariate analysis that included all other HCT-CI factors was 1.66, which was similar to the estimated HR (HR 1.6) reported by Sorror et al. 6 Our study confirmed the importance of pre-transplant DM as a risk factor of NRM in allogeneic HSCT.
This study is the first to demonstrate that pre-transplant DM is associated with an increased risk of infection-related deaths. The impact of pre-transplant hyperglycemia on the risk of infection during neutropenia has been discussed previously. 7 Derr et al. 7 reported that pre-transplant hyperglycemia was associated with an increased risk of post-transplant infectious diseases. Even though pre-transplant DM was not a risk factor of infectious diseases in a multivariate analysis in the current study, the incidence of infection-related NRM was significantly higher in patients with DM. This might reflect the vulnerability of patients with DM to infectious diseases. In particular, in terms of fungal disease, pre-transplant DM was associated with a highly increased risk of death (HR 3.51, 95%CI 2.05-6.03, P o0.01). Therefore, it might be beneficial to intensify the monitoring or the prophylaxis of fungal diseases in patients with DM. In addition, even though the overall incidence was low, the increased risk of mucor infection in patients with DM was significantly higher than in patients without DM (HR 9.91, 95% CI 2.99-32.88, P o0.01), which was consistent with previous observational studies. 23, 24 This finding suggests that, when patients with DM develop pneumonia that is suspected to involve Aspergillus or Mucor, it might be preferable to use antifungal agents that are active against Mucor, such as liposomal amphotericin B.
We also analyzed the relationship between pre-transplant DM and other factors of HCT-CI. Patients in the DM group were more likely to be complicated by arrhythmia, cerebrovascular disease, cardiac disease, mild hepatic disease, psychiatric disturbance, obesity and prior solid tumor than those in the non-DM group. This finding was consistent with previous reports. [25] [26] [27] [28] [29] [30] However, pre-transplant DM was an independent risk factor of NRM in a multivariate analysis that included all other HCT-CI factors. Furthermore, when patients were stratified according to the HCT-CI score that did not include DM, the incidence of NRM in patients with DM was higher than that in those without DM. In patients with an HCT-CI score of 0, NRM at 1 year in the DM group was two times higher than that in the non-DM group (32.8 vs 16.5%, Figures 2b and c) . With respect to patients with an HCT-CI score of 3 or more, 1-year NRM increased to over 52.6%. Thus, these results suggested that pre-transplant DM was associated with a poor clinical outcome independent of such coexisting comorbidities.
One possible intervention for improving the outcome could be intensive glucose control (IGC) after allogeneic HSCT. As reported previously, post-transplant hyperglycemia was common even in patients without pre-transplant DM. [8] [9] [10] Previous reports have shown that hyperglycemia is significantly associated with an increased risk of organ dysfunction, grade II-IV acute GVHD and NRM. [8] [9] [10] Therefore, we could assume that glucose control is more important in patients with pre-transplant DM. Our group recently published the results of an IGC protocol, and patients with the IGC protocol had a lower incidence of infectious diseases than a matched control cohort without IGC. 16 Even though most patients in that study did not have pre-transplant DM, IGC may offer similar benefits in patients with DM. The benefits of IGC in allogeneic HSCT for patients with DM should be assessed in future trials.
The limitations of this study should be clarified. Although this is the largest study to assess the impact of pre-transplant DM on the clinical outcome after allogeneic HSCT, as it was a retrospective analysis, we were not able to exclude the presence of uncontrolled confounding variables, even if we conducted multivariate analyzes for each clinical outcome. Thus, the present findings should be reevaluated using a different database to reconfirm the importance of pre-transplant DM. Furthermore, the data about the control of DM including the insulin-based protocols used for glycemic control should be also collected in future trials. In addition, even if pre-transplant DM was associated with an increased risk of NRM, this does not necessarily mean that intervention to normalize glucose control, so-called IGC, will Abbreviations: CB = cord blood; CI = confidence interval; DM = diabetes mellitus; HR = hazard ratio; MAC = myeloablative conditioning; PBSC = PB stem cell; PS = performance status; RIC = reduced-intensity conditioning.
improve the outcome, as demonstrated in the field of intensive care. 31, 32 The value of such interventions should be clarified in prospective studies in patients who undergo allogeneic HSCT.
In conclusion, pre-transplant DM was a significant and independent risk factor for NRM, especially infection-related deaths. To further improve the clinical outcome in patients with DM, the benefits of strict infection control and appropriate glycemic control in allogeneic HCT should be explored in future trials.
